Biofarm, (stock symbol BIO), one of the most important drug manufacturers in Romania, ended 2023 with a net profit of about 77 million lei, up 9% from the previous year and a turnover of approx. 280 million lei, according to preliminary results (unaudited).
"In 2023, we successfully implemented cost optimization strategies, focusing in particular on two of our company values: performance and end-consumer care. In doing so, we were able to identify effective ways to control our expenses, even in the context of rising raw material and packaging prices. The Consumer Healthcare category in Romania is becoming more and more competitive year by year, marked also by a slight decline in volumes in 2023 compared to 2022. However, we ended 2023 managing to consolidate our position on the market, with a positive evolution of the volume market share and to contribute positively on the quality of life of patients and consumers in Romania", said Cătălin Vicol, Biofarm CEO.
Biofarm continued to strengthen its market share in the Consumer Healthcare (CHC) segment, and ended 2023 in second position in terms of number of units sold.
The company dominates in value in 6 key categories across brands: Bixtonim, Triferment, Colebil, Extravalerianic, Carmol and Carbocit. In addition, Biofarm is the volume leader in no less than 8 categories, highlighting the outstanding performance of the brands Bixtonim, Colebil, Triferment, Sennalax, Extravalerianic, Carmol, Carbocit and Nervocalmin. These results confirm the success of Biofarm's approach and commitment to innovation. Through its achievements, the company continues to establish itself as a trusted player in Consumer Healthcare, offering effective and affordable solutions to consumers.
Biofarm has two drug factories in Bucharest and a product testing and development unit, and its portfolio of over 100 products covers the most important therapeutic areas of the Consumer Healthcare division (digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, nervous system). Constant innovation in the development of new products is one of the fundamental elements for Biofarm's expansion and strengthening its position among the leaders in the pharmaceutical industry.
The information provided by KomuniK
June is the richest month. The most awaited two weeks in my annual festival pilgrimage. The route starts with Romania’s Transilvania International Film Festival (TIFF), followed by Italy’s (and the world’s) most comprehensive festival for restored and archival film: Il Cinema Ritrovato. To shake up the traditional article on the two, I’ll start with the […]
Different Beauty, a recently opened exhibition of works by Czech photographer David Těšínský, offers a glimpse into everyday life in the war-torn region of Donbas in 2017. The photos were taken within the span of only a few days, as Těšínský traveled to eastern Ukraine to document the lives of women impacted by war. In […]
Different Beauty, a recently opened exhibition of works by Czech photographer David Těšínský, offers a glimpse into everyday life in the war-torn region of Donbas in 2017. The photos were taken within the span of only a few days, as Těšínský traveled to eastern Ukraine to document the lives of women impacted by war. In […]
Roughly 70% of Romanians are “very” or “moderately” concerned about how AI accesses and uses their data, according to the latest survey conducted by RoCoach in partnership with Novel Research between May and June 2025. Distrust in automated decision-making and the demand for regulation are becoming more pronounced, as Romania rolls out major digitalization projects […]
The Armenian Street Festival returns for a 9th edition between August 1 and 3, 2025, in the “Dimitrie Brândză” Botanical Garden in Bucharest. The festival brings into focus the living heritage of the Armenian community in Romania and the diaspora. According to the organizers, this year’s edition aims to strengthen the Bucharest–Chișinău–Yerevan cultural axis, articulated […]
The Romanian mergers and acquisitions market registered a total of 122 announced transactions in the first half of 2025, with a value exceeding EUR 2.7 billion, marking a slight increase of 6% in volume and 4% in value compared to the same period last year, according to an analysis by George Ureche, partner at PwC Romania. […]
